ArticleOncology letters2026
Overexpression and knockdown of 5-lipoxygenase regulates the migration and invasion of colorectal cancer cells.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overexpression of 5-lipoxygenase (5-LOX) plays a notable role in the development of colorectal cancer (CRC); however, the specific role of 5-LOX in the migration and invasion of CRC cells through the knockdown and overexpression of 5-LOX has not been well studied. Epithelial-mesenchymal transition (EMT) is associated with an invasive phenotype in CRC; however, the relationship between 5-LOX and EMT in CRC cells remains undefined. In the present study, the effects of 5-LOX overexpression and silencing on migration, invasion and EMT in CRC cells was investigated. In addition, the mRNA levels of vascular endothelial growth factor (VEGF) and angiogenin were also analyzed in human umbilical vein endothelial cells (HUVECs) when co-cultured with media acquired from 5-LOX-silenced or 5-LOX-overexpressed CRC cells. Reverse transcription-quantitative PCR and western blotting analyses were used to determine mRNA and protein expression levels, respectively. Transwell and wound healing assays were used to determine the invasion and migration ability of CRC cells. Fluorescent images were captured to demonstrate the lentiviral infection in CRC cells. Analysis revealed that the knockdown of 5-LOX by small interfering RNA significantly inhibited migration, invasion and EMT in HCT116 cells, whereas the overexpression of 5-LOX by recombinant lentiviruses significantly promoted migration, invasion and EMT in RKO cells. Media from 5-LOX-overexpressed RKO cells upregulated the expression of VEGF and angiogenin in HUVECs. These results demonstrated that the overexpression of 5-LOX promoted EMT in CRC cells, which may play a marked role in facilitating cellular migration and invasion. Furthermore, the tumor microenvironment of 5-LOX-overexpressed CRC cells may induce the angiogenesis in HUVECs. The present findings elucidate the role of 5-LOX in the migration and invasion of CRC cells via the knockdown and overexpression of the 5-LOX gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.